West Pharmaceutical Services, Inc. logo

West Pharmaceutical Services, Inc.

WST

NYSEHealthcareMedical - Instruments & Supplies

Previous close

$353.08

−$0.69 · -0.20%

Aug 21, 4:00 PM ET

WST company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

49

Fair Value

Momentum

57

Neutral

Sentiment

70

Bullish

Risk resilience

77

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Eric Green
Listed since
Mar 17, 1980
Employees
10,800

Market position

Day range

Current $353.08

52-week range

Current $353.08

Open
$356.88
Previous close
$353.77
Volume
424.73K
0.53× average
Average volume
804.13K
Average daily volume
Market cap
24.85B USD
Beta
1.14
Market reference 1
50-day average
$347.81
+1.52% above average
200-day average
$290.2
+21.67% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
19.52B USD
P/E (TTM)
44.86×
P/B (TTM)
8.36×
P/S (TTM)
7.47×
EV / EBITDA
26.97×
Earnings yield
2.48%
Free cash flow yield
2.36%
Dividend yield
0.25%

Profitability & efficiency

Gross margin
36.77%
Operating margin
20.64%
Net margin
16.98%
Return on equity
15.54%
Return on assets
11.56%
Return on invested capital
13.62%

Financial health

Debt / equity
0.1×
Current ratio
3.02×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends44%34%24%14%Gross margin, FY2021: 41.45%Gross margin, FY2022: 39.47%Gross margin, FY2023: 38.38%Gross margin, FY2024: 34.65%Gross margin, FY2025: 35.89%Operating margin, FY2021: 26.80%Operating margin, FY2022: 26.46%Operating margin, FY2023: 24.09%Operating margin, FY2024: 20.56%Operating margin, FY2025: 20.09%Net margin, FY2021: 23.38%Net margin, FY2022: 20.30%Net margin, FY2023: 20.11%Net margin, FY2024: 17.03%Net margin, FY2025: 16.06%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 41.45%. Gross margin FY2022 39.47%. Gross margin FY2023 38.38%. Gross margin FY2024 34.65%. Gross margin FY2025 35.89%. Operating margin FY2021 26.80%. Operating margin FY2022 26.46%. Operating margin FY2023 24.09%. Operating margin FY2024 20.56%. Operating margin FY2025 20.09%. Net margin FY2021 23.38%. Net margin FY2022 20.30%. Net margin FY2023 20.11%. Net margin FY2024 17.03%. Net margin FY2025 16.06%.

Income trends

Revenue

3.07B USD+6.26%

Operating income

617.4M USD+3.83%

Net income

493.7M USD+0.20%
Income trends across reported periods3.33B USD2.3B USD1.27B USD234.6M USDRevenue, FY2021: 2.83B USDRevenue, FY2022: 2.89B USDRevenue, FY2023: 2.95B USDRevenue, FY2024: 2.89B USDRevenue, FY2025: 3.07B USDOperating income, FY2021: 758.7M USDOperating income, FY2022: 763.5M USDOperating income, FY2023: 710.9M USDOperating income, FY2024: 594.6M USDOperating income, FY2025: 617.4M USDNet income, FY2021: 661.8M USDNet income, FY2022: 585.9M USDNet income, FY2023: 593.4M USDNet income, FY2024: 492.7M USDNet income, FY2025: 493.7M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 2.83B USD. Revenue FY2022 2.89B USD. Revenue FY2023 2.95B USD. Revenue FY2024 2.89B USD. Revenue FY2025 3.07B USD. Operating income FY2021 758.7M USD. Operating income FY2022 763.5M USD. Operating income FY2023 710.9M USD. Operating income FY2024 594.6M USD. Operating income FY2025 617.4M USD. Net income FY2021 661.8M USD. Net income FY2022 585.9M USD. Net income FY2023 593.4M USD. Net income FY2024 492.7M USD. Net income FY2025 493.7M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.07B USD2.89B USD2.95B USD2.89B USD2.83B USD
Cost of goods sold1.97B USD1.89B USD1.82B USD1.75B USD1.66B USD
Gross profit1.1B USD1B USD1.13B USD1.14B USD1.17B USD
Research and development74.3M USD69.1M USD68.4M USD58.5M USD52.8M USD
Selling, general, and administrative393.1M USD338.5M USD353.4M USD316.9M USD361.9M USD
Operating expenses485.9M USD407.6M USD421.8M USD375.4M USD414.7M USD
Interest income17.7M USD19.6M USD28M USD5.1M USD1M USD
Interest expense600K USD2.9M USD8.8M USD7.6M USD8.5M USD
Depreciation and amortization124.4M USD155.4M USD137.3M USD120.6M USD122.3M USD
Operating income617.4M USD594.6M USD710.9M USD763.5M USD758.7M USD
Net income493.7M USD492.7M USD593.4M USD585.9M USD661.8M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

9 institutions
CitigroupmaintainBuy
B of A SecuritiesmaintainBuy

WST peers

ETFs holding WST

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research WST

research.disclaimer